BACKGROUND: Over 10,000 US @entity1 are diagnosed with @entity5 yearly. Though outcomes have improved by optimizing conventional therapies, recent immunotherapeutic successes in adult @entity5 are @entity341 . Cytotoxic T lymphocytes (CTLs) are the primary executioners of adaptive antitumor immunity and require antigenic presentation in the context of major histocompatibility complex (MHC) class I and the associated @entity6393 ( @entity6393 ). Loss of MHC I expression is a common immune escape mechanism in @entity5 , but pediatric @entity5 have not been thoroughly characterized. The essential nature of MHC I expression in CTL-mediated cell death may dictate the success of immunotherapies, which rely on eliciting an adaptive response. PROCEDURE: We queried @entity5 microarray databases for MHC I and @entity6393 gene expression. We detected MHC I in @entity5 cell lines by flow cytometry and characterized MHC I and @entity6393 expression in @entity1 samples by immunohistochemistry. To determine whether therapeutic approaches might enhance MHC I expression in selected models in vitro, we tested effects of exposure to @entity379 and histone deacetylase inhibitors. RESULTS: @entity5 overall, as well as samples within select individual @entity5 subtypes, exhibit wide ranges of MHC I and @entity6393 gene and protein expression. For most cell lines tested, MHC I was inducible in vitro. CONCLUSIONS: MHC I and @entity6393 expression vary among @entity5 types and should be evaluated as potential biomarkers, which might identify @entity1 most likely to benefit from MHC I dependent immunotherapies. Modulation of MHC I expression may be a promising mechanism for enhancing MHC I dependent immunotherapeutic efficacy.

Characterization of MHC Class I and XXXX Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'adult malignancies', 'Pediatric tumors', 'cancers', 'cancer', 'pediatric tumor'] @entity341 :: ('MESH:D004630', 'Disease') :: ['emerging'] @entity379 :: ('3458', 'Gene') :: ['IFN-y'] @entity6393 :: ('3135', 'Gene') :: ['b-2-microglobulin', 'B2M']
@entity6393 :: (3135,Gene) :: ['b-2-Microglobulin']
